301201.SZ Stock Analysis
30
Uncovered
Chengda Pharmaceuticals Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Chengda Pharmaceuticals Co., Ltd. manufactures active pharmaceutical ingredients, food additives, fertilizer additives, antibiotics, and pharmaceutical intermediates. The company is headquartered in Jiaxing, Zhejiang and currently employs 461 full-time employees. The company went IPO on 2022-01-20. The firm is also engaged in the production and sales of L-carnitine series products and active pharmaceutical ingredients (APIs). The pharmaceutical intermediate products include NP0805/NP0908, NP1205, NP0806, NP1011/1214, NP1709 and others. The L-carnitine series products are used in the fields of food additives, feed additives and raw materials. The APIs products include Buwaxitan, Vidagliptin, Elagoli and others. The firm's products are exported to the United States, Europe, Japan, Canada, the United Kingdom, Italy and other countries and regions.